Highly Sensitive Viral Detection with the SARS-CoV-2 NGS Assay

Kristin Butcher and Mara Cuoto-Rodriguez discuss the development of a nucleic acid hybridization capture-based assay to detect and identify novel SARS-CoV-2 variants.

The Scientist Staff
Apr 15, 2021

FREE Webinar

Thursday, May 20, 2021
12:00 - 1:30 PM Eastern Time

Register Now

The COVID-19 pandemic highlights a need for the rapid development of detection strategies and assays for novel pathogens. The SARS-CoV-2 NGS Assay is a highly sensitive nucleic acid hybridization capture-based assay that detects the SARS-CoV-2 viral genome. This FDA-authorized-under-emergency-use assay combines virus-specific panels and comprehensive data analysis software and reporting capabilities to provide researchers with information on genetic variants, clade-associated variants, and phylogenetics. In this webinar brought to you by Twist Bioscience, Kristin Butcher and Mara Cuoto-Rodriguez will demonstrate the SARS-CoV-2 NGS assay technology and describe how researchers use it to detect and identify novel variants of the SARS-CoV-2 virus.

Topics to be covered

  • The end-to-end SARS-CoV-2 NGS assay workflow
  • The benefits of hybrid-capture technology and COVID-DX software
  • How Biotia’s COVID-DX pipeline determines the presence or absence of SARS-CoV-2, identifies genetic variants, estimates viral clades, and generates phylogenetic trees

Register Now

Meet the Speakers:

Kristin Butcher
Senior Scientist
Twist Bioscience


Mara Couto-Rodriguez
Director of Research and Development
Biotia



Sponsored by